Saliva Testing Growth Leverage the strong momentum from their FDA EUA-cleared SARS-CoV-2 saliva test and ongoing mass testing partnerships to position broader diagnostic panels and ongoing surveillance services for institutions and public health programs.

Partnership Network Target expansion opportunities with RUCDR Infinite Biologics, Rutgers University collaborations, and Middlesex County partners to offer end-to-end testing solutions, sample collection kits, and data integration for healthcare systems.

Clinical Scale Readiness Capitalize on recent deployments and capacity announcements to offer scalable laboratory services, including antibody testing (IgG/IgM) and high-throughput workflows, to regional hospitals, clinics, and long-term care facilities.

Mid-market Focus With revenue in the 10M–25M range and a mid-sized employee base, pursue mid-market hospital networks, independent labs, and regional health systems seeking specialized testing capabilities and cost efficiencies.

Digital & Compliance Promote technology stack strengths (secure web services, mapping, validation tooling) as enablers for compliant data management, patient access, and rapid integration with existing EHR and lab information systems.